Gw Pharma ADR (GWPH) 94.83 $GWPH
Catabasis' DMD Drug in Phase II Open-Label Extension Study
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:28AM CDT
Catabasis (CATB) initiated an open-label extension for the phase II portion (Part
of its MoveDMD study on edasalonexent for the treatment of DMD.
BMRN: 91.49 (+3.33), CATB: 3.69 (+0.16), GWPH: 94.83 (+1.36), SRPT: 22.62 (+1.70)
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 115.00 (+1.34), NXTM: 22.91 (+1.07), GWPH: 94.83 (+1.36), ILMN: 141.25 (+1.19)
Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.62 (unch), INVA: 11.64 (+0.26), GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58)
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58), PFE: 36.12 (+0.35)
Cardiovascular Systems Seeks Device Approval in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:49AM CDT
On receiving the approval, Japan will become the first international market to offer a product of Cardiovascular Systems (CSII).
HCM: 13.76 (+0.42), CSII: 19.62 (+1.12), GWPH: 94.83 (+1.36), NUVA: 60.82 (+1.11)
GW Pharmaceuticals (GWPH): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:36AM CDT
GW Pharmaceuticals is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
GWPH: 94.83 (+1.36)
Lantheus Holdings (LNTH) Catches Eye: Stock Jumps 15.3%
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:30AM CDT
Lantheus Holdings, Inc. (LNTH) shares rose over 15% in the last trading session.
GWPH: 94.83 (+1.36), LNTH: 4.65 (+0.27)
Walgreens Boots Tops Q3 Earnings, Rite Aid Deal on Track
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 10:46AM CDT
Walgreens Boots (WBA) reported a mixed third-quarter fiscal 2016 with earnings comfortably beating the Zacks Consensus Estimate, while the top line closely missed the mark.
ICUI: 115.00 (+1.34), WBA: 81.80 (+1.30), GWPH: 94.83 (+1.36), TGTX: 6.16 (+0.05)
Merck to Acquire Brazilian Animal Health Company for $400M
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:28AM CDT
Merck (MRK) announced that it will acquire the controlling interest in Vallee S.A., a Brazil-based privately held producer of animal health products.
GWPH: 94.83 (+1.36), ANIP: 56.51 (-1.61), UTHR: 111.16 (+1.58), MRK: 59.35 (+0.57)
NuVasive (NUVA) at 52-Week High on Strategic Initiatives
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 8:03AM CDT
Currently, NuVasive (NUVA) expects its international business to grow by 38% in 2016, at CER.
BSX: 23.90 (+0.24), ICUI: 115.00 (+1.34), GWPH: 94.83 (+1.36), NUVA: 60.82 (+1.11)
New Strong Buy Stocks for July 5th
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 7:55AM CDT
New Strong Buy Stocks for July 5th
GWPH: 94.83 (+1.36), MDSO: 48.17 (+1.14), CYTR: 2.26 (+0.04), DNR: 3.22 (+0.10), IPDN: 0.48 (+0.02)
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
GWPH: 94.83 (+1.36), MDCO: 34.90 (+0.51), GILD: 86.55 (+1.08), RGLS: 3.50 (+0.07), ABBV: 64.16 (+0.73)
Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jun 29, 1:23PM CDT
Most biotech stocks were down reflecting uncertainty regarding the impact of Brexit on the sector especially companies which generate significant sales in the EU.
GWPH: 94.83 (+1.36), GILD: 86.55 (+1.08), MDCO: 34.90 (+0.51), ALXN: 124.42 (+1.08), RGLS: 3.50 (+0.07), ABBV: 64.16 (+0.73), XNCR: 18.62 (+0.08)
GW Pharmaceuticals (GWPH) Catches Eye: Stock Gains 6.2%
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 7:45AM CDT
GW Pharmaceuticals plc (GWPH) was a big mover last session, as the company saw its shares rise over 6% on the day.
BSX: 23.90 (+0.24), GWPH: 94.83 (+1.36)
GW Pharmaceuticals Stock Up on Positive Epidiolex Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 7:33AM CDT
GW Pharmaceuticals (GWPH) announced positive data from the first phase III study on Epidiolex for the treatment of Lennox-Gastaut syndrome.
GWPH: 94.83 (+1.36), ANIP: 56.51 (-1.61), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
GlobeNewswire - Mon Jun 27, 6:00AM CDT
- Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo -
GWPH: 94.83 (+1.36)
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 94.83 (+1.36), ANIP: 56.51 (-1.61), RTRX: 18.65 (+0.35), BMY: 75.28 (+1.20)
Will Medical Marijuana Take Biotech Stocks To A New High?
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / If marijuana brings words like smoke, pot, weed and grass to your mind, it's time to change that picture to medicine, cure and relief. For the medical marijuana industry, what comes to mind are words like high sales, profit growth potential and stock market catalyst.
XXII: 0.82 (+0.02), GWPH: 94.83 (+1.36)
NTRR: Cannabis' Better-than-Expected Tax Revenues Could Speed Legalization Efforts
ACCESSWIRE - Wed Jun 08, 4:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 8, 2016 / Legalized cannabis has created tax windfalls for Washington and Colorado, and other states currently on the legalization fence are enviously and eagerly eyeing those results. For Neutra Corp. (OTCQB: NTRR), this scenario could create a positive environment for its cannabis-related business as more and more revenue-hungry states approve the substance for adult recreational use to grab additional tax monies.
XXII: 0.82 (+0.02), CARA: 5.18 (+0.09), GWPH: 94.83 (+1.36)
NTRR Aiming to Acquire Medical Marijuana Facility, Starts Talks on Colorado Sites
ACCESSWIRE - Thu Jun 02, 4:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 2, 2016 / Neutra Corp. (OTCQB: NTRR) is opening discussions on acquiring a 100 percent interest in a medical marijuana dispensary and/or cultivation center in Colorado and has narrowed its focus to several promising and available locations in the Centennial State. The company is also looking over similar facilities in California.
XXII: 0.82 (+0.02), CARA: 5.18 (+0.09), GWPH: 94.83 (+1.36)
Catabasis' DMD Drug in Phase II Open-Label Extension Study
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:28AM CDT
Catabasis (CATB) initiated an open-label extension for the phase II portion (Part
of its MoveDMD study on edasalonexent for the treatment of DMD. BMRN: 91.49 (+3.33), CATB: 3.69 (+0.16), GWPH: 94.83 (+1.36), SRPT: 22.62 (+1.70)
Illumina Stock Hit by Downbeat Guidance, Stiff Competition
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:27AM CDT
Illumina (ILMN) faces high expenses related to the development of new products, their launch in various markets and investments in partnerships
ICUI: 115.00 (+1.34), NXTM: 22.91 (+1.07), GWPH: 94.83 (+1.36), ILMN: 141.25 (+1.19)
Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.62 (unch), INVA: 11.64 (+0.26), GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58)
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 94.83 (+1.36), UTHR: 111.16 (+1.58), PFE: 36.12 (+0.35)
Cardiovascular Systems Seeks Device Approval in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:49AM CDT
On receiving the approval, Japan will become the first international market to offer a product of Cardiovascular Systems (CSII).
HCM: 13.76 (+0.42), CSII: 19.62 (+1.12), GWPH: 94.83 (+1.36), NUVA: 60.82 (+1.11)
GW Pharmaceuticals (GWPH): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:36AM CDT
GW Pharmaceuticals is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
GWPH: 94.83 (+1.36)
Lantheus Holdings (LNTH) Catches Eye: Stock Jumps 15.3%
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:30AM CDT
Lantheus Holdings, Inc. (LNTH) shares rose over 15% in the last trading session.
GWPH: 94.83 (+1.36), LNTH: 4.65 (+0.27)
Walgreens Boots Tops Q3 Earnings, Rite Aid Deal on Track
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 10:46AM CDT
Walgreens Boots (WBA) reported a mixed third-quarter fiscal 2016 with earnings comfortably beating the Zacks Consensus Estimate, while the top line closely missed the mark.
ICUI: 115.00 (+1.34), WBA: 81.80 (+1.30), GWPH: 94.83 (+1.36), TGTX: 6.16 (+0.05)
Merck to Acquire Brazilian Animal Health Company for $400M
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 10:28AM CDT
Merck (MRK) announced that it will acquire the controlling interest in Vallee S.A., a Brazil-based privately held producer of animal health products.
GWPH: 94.83 (+1.36), ANIP: 56.51 (-1.61), UTHR: 111.16 (+1.58), MRK: 59.35 (+0.57)
NuVasive (NUVA) at 52-Week High on Strategic Initiatives
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 8:03AM CDT
Currently, NuVasive (NUVA) expects its international business to grow by 38% in 2016, at CER.
BSX: 23.90 (+0.24), ICUI: 115.00 (+1.34), GWPH: 94.83 (+1.36), NUVA: 60.82 (+1.11)
New Strong Buy Stocks for July 5th
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 7:55AM CDT
New Strong Buy Stocks for July 5th
GWPH: 94.83 (+1.36), MDSO: 48.17 (+1.14), CYTR: 2.26 (+0.04), DNR: 3.22 (+0.10), IPDN: 0.48 (+0.02)
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
GWPH: 94.83 (+1.36), MDCO: 34.90 (+0.51), GILD: 86.55 (+1.08), RGLS: 3.50 (+0.07), ABBV: 64.16 (+0.73)
Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jun 29, 1:23PM CDT
Most biotech stocks were down reflecting uncertainty regarding the impact of Brexit on the sector especially companies which generate significant sales in the EU.
GWPH: 94.83 (+1.36), GILD: 86.55 (+1.08), MDCO: 34.90 (+0.51), ALXN: 124.42 (+1.08), RGLS: 3.50 (+0.07), ABBV: 64.16 (+0.73), XNCR: 18.62 (+0.08)
GW Pharmaceuticals (GWPH) Catches Eye: Stock Gains 6.2%
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 7:45AM CDT
GW Pharmaceuticals plc (GWPH) was a big mover last session, as the company saw its shares rise over 6% on the day.
BSX: 23.90 (+0.24), GWPH: 94.83 (+1.36)
GW Pharmaceuticals Stock Up on Positive Epidiolex Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 7:33AM CDT
GW Pharmaceuticals (GWPH) announced positive data from the first phase III study on Epidiolex for the treatment of Lennox-Gastaut syndrome.
GWPH: 94.83 (+1.36), ANIP: 56.51 (-1.61), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
GlobeNewswire - Mon Jun 27, 6:00AM CDT
- Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo -
GWPH: 94.83 (+1.36)
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 94.83 (+1.36), ANIP: 56.51 (-1.61), RTRX: 18.65 (+0.35), BMY: 75.28 (+1.20)
Will Medical Marijuana Take Biotech Stocks To A New High?
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / If marijuana brings words like smoke, pot, weed and grass to your mind, it's time to change that picture to medicine, cure and relief. For the medical marijuana industry, what comes to mind are words like high sales, profit growth potential and stock market catalyst.
XXII: 0.82 (+0.02), GWPH: 94.83 (+1.36)
NTRR: Cannabis' Better-than-Expected Tax Revenues Could Speed Legalization Efforts
ACCESSWIRE - Wed Jun 08, 4:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 8, 2016 / Legalized cannabis has created tax windfalls for Washington and Colorado, and other states currently on the legalization fence are enviously and eagerly eyeing those results. For Neutra Corp. (OTCQB: NTRR), this scenario could create a positive environment for its cannabis-related business as more and more revenue-hungry states approve the substance for adult recreational use to grab additional tax monies.
XXII: 0.82 (+0.02), CARA: 5.18 (+0.09), GWPH: 94.83 (+1.36)
NTRR Aiming to Acquire Medical Marijuana Facility, Starts Talks on Colorado Sites
ACCESSWIRE - Thu Jun 02, 4:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 2, 2016 / Neutra Corp. (OTCQB: NTRR) is opening discussions on acquiring a 100 percent interest in a medical marijuana dispensary and/or cultivation center in Colorado and has narrowed its focus to several promising and available locations in the Centennial State. The company is also looking over similar facilities in California.
XXII: 0.82 (+0.02), CARA: 5.18 (+0.09), GWPH: 94.83 (+1.36)
